NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.88
  • Forecasted Upside: 35.54 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.81
▲ +0.08 (1.40%)

This chart shows the closing price for CPRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Catalyst Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CPRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CPRX

Analyst Price Target is $7.88
▲ +35.54% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Catalyst Pharmaceuticals in the last 3 months. The average price target is $7.88, with a high forecast of $11.00 and a low forecast of $5.50. The average price target represents a 35.54% upside from the last price of $5.81.

This chart shows the closing price for CPRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Catalyst Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/12/2021Cantor FitzgeraldBoost Price Target$8.00 ➝ $11.00Medium
3/18/2021Roth CapitalBoost Price TargetBuy$6.50 ➝ $7.00Medium
11/10/2020Piper SandlerLower Price TargetOverweight$6.00 ➝ $5.50Low
8/11/2020Roth CapitalReiterated RatingBuyMedium
8/11/2020Piper SandlerLower Price Target$7.00 ➝ $6.00Low
8/4/2020OppenheimerReiterated RatingBuy$8.00Low
5/13/2020SunTrust BanksLower Price TargetBuy$11.00 ➝ $10.00High
2/14/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $12.00High
12/23/2019HC WainwrightReiterated RatingBuy$9.00Medium
11/13/2019Piper Jaffray CompaniesLower Price Target$8.00 ➝ $7.00High
10/31/2019HC WainwrightReiterated RatingBuy$9.00High
10/9/2019Piper Jaffray CompaniesSet Price TargetBuy$8.00N/A
8/8/2019Cantor FitzgeraldBoost Price Target$10.00 ➝ $12.00Low
8/8/2019SunTrust BanksReiterated RatingBuy$9.00 ➝ $11.00High
5/14/2019HC WainwrightSet Price TargetBuy$9.00High
5/7/2019Cantor FitzgeraldReiterated RatingBuy$10.00High
3/19/2019Cantor FitzgeraldReiterated RatingBuy$10.00Low
12/14/2018HC WainwrightReiterated RatingBuyHigh
12/13/2018Cantor FitzgeraldSet Price TargetBuy$9.00High
12/13/2018Piper Jaffray CompaniesBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $7.50Low
11/29/2018OppenheimerSet Price TargetBuy$6.00Low
11/28/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
11/9/2018HC WainwrightReiterated RatingBuy$6.00High
11/8/2018OppenheimerSet Price TargetBuy$6.00High
11/8/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
10/26/2018Cantor FitzgeraldSet Price TargetBuy$8.00Medium
10/16/2018OppenheimerSet Price TargetBuy$6.00Low
10/3/2018Cantor FitzgeraldSet Price TargetBuy$8.00Low
9/21/2018Cantor FitzgeraldInitiated CoverageOverweightHigh
9/20/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$8.00High
9/7/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$5.00Medium
8/22/2018HC WainwrightSet Price TargetBuy$6.00High
8/9/2018OppenheimerSet Price TargetBuy$6.00High
8/9/2018HC WainwrightReiterated RatingBuy$6.00High
7/12/2018OppenheimerInitiated CoverageBuy$6.00High
3/15/2018HC WainwrightReiterated RatingBuy$6.00High
12/21/2017HC WainwrightReiterated RatingBuy$6.00High
12/1/2017Piper Jaffray CompaniesSet Price TargetPositive ➝ Buy$8.00Low
11/29/2017SunTrust BanksReiterated RatingBuy$6.00High
11/10/2017HC WainwrightReiterated RatingBuy$6.00N/A
11/1/2017Roth CapitalSet Price TargetBuy$5.00N/A
10/31/2017SunTrust BanksSet Price TargetBuy$5.00N/A
9/5/2017SunTrust BanksReiterated RatingBuy$5.00High
8/10/2017Roth CapitalSet Price TargetBuy$5.00Low
8/7/2017Piper Jaffray CompaniesSet Price TargetBuy$6.00Low
3/20/2017Roth CapitalSet Price TargetBuy$3.00Low
3/20/2017HC WainwrightReiterated RatingBuy$6.00Low
10/14/2016Roth CapitalReiterated RatingBuy$2.50N/A
10/5/2016Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$4.00N/A
(Data available from 6/21/2016 forward)
Catalyst Pharmaceuticals logo
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS) and myasthenia gravis; and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Read More

Today's Range

Now: $5.81
Low: $5.69
High: $5.81

50 Day Range

MA: $5.14
Low: $4.29
High: $5.81

52 Week Range

Now: $5.81
Low: $2.88
High: $5.90

Volume

21,204 shs

Average Volume

1,551,026 shs

Market Capitalization

$600.54 million

P/E Ratio

8.54

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Catalyst Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Catalyst Pharmaceuticals in the last twelve months: Cantor Fitzgerald, Oppenheimer Holdings Inc., Piper Sandler, Roth Capital, and TheStreet.
View the latest analyst ratings for CPRX.

What is the current price target for Catalyst Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Catalyst Pharmaceuticals in the last year. Their average twelve-month price target is $7.88, suggesting a possible upside of 35.5%. Cantor Fitzgerald has the highest price target set, predicting CPRX will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $5.50 for Catalyst Pharmaceuticals in the next year.
View the latest price targets for CPRX.

What is the current consensus analyst rating for Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CPRX will outperform the market and that investors should add to their positions of Catalyst Pharmaceuticals.
View the latest ratings for CPRX.

What other companies compete with Catalyst Pharmaceuticals?

How do I contact Catalyst Pharmaceuticals' investor relations team?

Catalyst Pharmaceuticals' physical mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company's listed phone number is 305-420-3200 and its investor relations email address is [email protected] The official website for Catalyst Pharmaceuticals is www.catalystpharma.com.